论文部分内容阅读
对６２例晚期肺癌胸水中肿瘤碱性蛋白（ＴＢＰ）、癌胚抗原（ＣＥＡ）和总唾液酸（ＴＳＡ）进行检测，结果显示有９６．７７％病人的ＴＢＰ电泳阳性、ＣＥＡ及ＴＳＡ处在高水平，明显高于细胞学诊断率。治疗效果明显时病人的ＴＢＰ电泳转阴率达９０．９１％，ＣＥＡ和ＴＳＡ也由治疗前的２６．７μｇ／Ｌ、３２．４μｇ／Ｌ和５８３．４ｍｇ／Ｌ、５５９．２ｍｇ／Ｌ分别下降至６．２μｇ／Ｌ、８．４μｇ／Ｌ和３４９．６ｍｇ／Ｌ、３９６．３ｍｇ／Ｌ。本研究提示胸水中３种糖蛋白的测定可作为鉴别恶性胸水和对肺癌治疗结果的判定标准，这还有利于临床医生动态地观察疾病的治疗情况，以便适时地调整治疗方案。
The detection of tumor basic protein (TBP), carcinoembryonic antigen (CEA), and total sialic acid (TSA) in 62 cases of advanced lung cancer pleural effusion showed that 96.77% of patients had positive TBP electrophoresis, and CEA and TSA were high. The level is significantly higher than the cytological diagnostic rate. When the treatment effect was obvious, the patient’s TBP electrophoretic negative rate was 90.91%. CEA and TSA also decreased from 26.7 μg/L, 32.4 μg/L, 583.4 mg/L, and 559.2 mg/L respectively before treatment. To 6.2 μg/L, 8.4 μg/L and 349.6 mg/L, 396.3 mg/L. This study suggests that the determination of three kinds of glycoproteins in pleural effusions can be used as a criterion for judging malignant pleural effusions and treatment outcomes of lung cancer. This is also beneficial for clinicians to dynamically observe the treatment of diseases so as to timely adjust the treatment plan.